Dementia Drug May Combat Alcohol Withdrawal

Researchers are exploring an experimental dementia drug, MW150, as a potential treatment for alcohol withdrawal. The medication targets a brain inflammation pathway, p38α MAPK, which scientists believe plays a role in addiction and relapse in individuals with alcohol use disorder.

Initial studies using cell cultures and animal models, published in the journal Alcohol, indicated that MW150 could decrease inflammatory markers associated with alcohol withdrawal. This neuroinflammatory aspect is considered significant because high relapse rates during withdrawal pose a major challenge in treating alcohol use disorder.

The drug MW150 is already being investigated in clinical trials for Alzheimer's disease and other neurodegenerative conditions. This existing development pathway could potentially expedite its repurposing for alcohol-related issues if further research confirms its efficacy and safety.

Experts caution that the research is preliminary, based on laboratory models. Further studies in living animals are necessary to understand the drug's effects on the entire organism and its impact on alcohol consumption and overall health. Nevertheless, the potential to address neuroinflammation could fill a critical gap in early treatment for alcohol use disorder.